Identification

Name
Fluoxetine
Accession Number
DB00472  (APRD00530)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs). Fluoxetine is a racemic mixture of the R- and S- enantiomers and are of equivalent pharmacologic activity. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Fluoxetine may be used to treat major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and in combination with olanzapine for treatment-resistant or bipolar I depression. Fluoxetine is the most anorexic and stimulating SSRI.

Structure
Thumb
Synonyms
  • (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
  • (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
  • Fluoxetin
  • Fluoxetina
  • Fluoxétine
  • Fluoxetinum
External IDs
Lilly 103472 / Lilly 110 140
Product Ingredients
IngredientUNIICASInChI Key
Fluoxetine HydrochlorideI9W7N6B1KJ56296-78-7GIYXAJPCNFJEHY-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-fluoxetineCapsule20 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-fluoxetineCapsule10 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Ach-fluoxetineCapsule20 mgOralAccord Healthcare Limited2012-05-01Not applicableCanada
Ach-fluoxetineCapsule10 mgOralAccord Healthcare Limited2012-10-10Not applicableCanada
Act FluoxetineCapsule10 mgOralDr Reddy's Laboratories2000-05-31Not applicableCanada
Act FluoxetineCapsule20 mgOralDr Reddy's Laboratories2000-05-31Not applicableCanada
Act FluoxetineCapsule40 mgOralDr Reddy's LaboratoriesNot applicableNot applicableCanada
Auro-fluoxetineCapsule10 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-fluoxetineCapsule20 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Ava-fluoxetineCapsule20 mgOralAvanstra Inc2011-11-282014-08-21Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fluoxetineSolution20 mgOralApotex Corporation1997-06-16Not applicableCanada
Apo-fluoxetineCapsule20 mgOralApotex Corporation1996-12-31Not applicableCanada
Apo-fluoxetineCapsule10 mgOralApotex Corporation1996-12-31Not applicableCanada
FluoxetineCapsule20 mg/1OralClinical Solutions Wholsesale2002-01-29Not applicableUs
FluoxetineCapsule20 mg/1OralRemedy Repack2013-06-032016-04-05Us
FluoxetineSolution20 mg/5mLOralPharmaceutical Associates, Inc.2002-01-30Not applicableUs
FluoxetineCapsule40 mg/1OralDr Reddy's Laboratories2002-10-15Not applicableUs
FluoxetineTablet, film coated10 mg/1OralProficient Rx LP2002-01-30Not applicableUs00093 7188 56 nlmimage10 f92d7ccb
FluoxetineCapsule20 mg/1Oralbryant ranch prepack2008-01-31Not applicableUs
FluoxetineCapsule40 mg/1OralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FluoxetineCapsule40 mg/1OralDirectrx2017-10-30Not applicableUs
FluoxetineCapsule10 mg/1OralDirectrx2017-11-06Not applicableUs
FluoxetineCapsule10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-01-29Not applicableUs
International/Other Brands
Adofen (Brainpharma) / Animex-On (Laboratorios) / Fluoxeren (Menarini) / Fontex (Lilly) / Ladose (Lilly) / Prozac
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
GaboxetineFluoxetine Hydrochloride + CholineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
Olanzapine and FluoxetineFluoxetine Hydrochloride (50 mg/1) + Olanzapine (12 mg/1)CapsuleOralPar Pharmaceutical2012-11-28Not applicableUs
Olanzapine and FluoxetineFluoxetine Hydrochloride (25 mg/1) + Olanzapine (12 mg/1)CapsuleOralSandoz2012-11-30Not applicableUs
Olanzapine and FluoxetineFluoxetine Hydrochloride (50 mg/1) + Olanzapine (6 mg/1)CapsuleOralTeva2012-06-19Not applicableUs
Olanzapine and FluoxetineFluoxetine Hydrochloride (25 mg/1) + Olanzapine (3 mg/1)CapsuleOralAv Kare, Inc.2014-01-21Not applicableUs
Olanzapine and FluoxetineFluoxetine Hydrochloride (25 mg/1) + Olanzapine (6 mg/1)CapsuleOralSandoz2012-11-30Not applicableUs
Olanzapine and FluoxetineFluoxetine Hydrochloride (25 mg/1) + Olanzapine (12 mg/1)CapsuleOralAv Kare, Inc.2014-01-21Not applicableUs00093 5506 56 nlmimage10 1e270f18
Olanzapine and FluoxetineFluoxetine Hydrochloride (25 mg/1) + Olanzapine (3 mg/1)CapsuleOralSandoz2012-11-30Not applicableUs
Olanzapine and FluoxetineFluoxetine Hydrochloride (25 mg/1) + Olanzapine (3 mg/1)CapsuleOralTeva2013-04-10Not applicableUs00093 5503 56 nlmimage10 a8365432
Olanzapine and FluoxetineFluoxetine Hydrochloride (50 mg/1) + Olanzapine (6 mg/1)CapsuleOralPar Pharmaceutical2012-11-28Not applicableUs
Categories
UNII
01K63SUP8D
CAS number
54910-89-3
Weight
Average: 309.3261
Monoisotopic: 309.134048818
Chemical Formula
C17H18F3NO
InChI Key
RTHCYVBBDHJXIQ-UHFFFAOYSA-N
InChI
InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
IUPAC Name
methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
SMILES
CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1

Pharmacology

Indication

Labeled indication include: major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and combination treatment with olanzapine for treatment-resistant or bipolar I depression. Unlabeled indications include: selective mutism, mild dementia-associated agitation in nonpsychotic patients, post-traumatic stress disorder (PTSD), social anxiety disorder, chronic neuropathic pain, fibromyalgia, and Raynaud's phenomenon.

Structured Indications
Pharmacodynamics

Fluoxetine, an antidepressant agent belonging to the selective serotonin reuptake inhibitors (SSRIs), is used to treat depression, bulimia nervosa, premenstrual dysphoric disorder, panic disorder and post-traumatic stress. According to the amines hypothesis, a functional decrease in the activity of amines, such as serotonin and norepinephrine, would result in depression; a functional increase of the activity of these amines would result in mood elevation. Fluoxetine's effects are thought to be associated with the inhibition of 5HT receptor, which leads to an increase of serotonin level. Antagonism of muscarinic, histaminergic, and α1–adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of classical tricyclic antidepressant (TCA) drugs. Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs.

Mechanism of action

Metabolized to norfluoxetine, fluoxetine is a selective serotonin-reuptake inhibitor (SSRI), it blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
UCyclin-dependent kinases regulatory subunit 1Not AvailableHuman
Absorption

Well absorbed from the GI tract following oral administration. Oral bioavailability is estimated to be at least 60-80%. Peak plasma concentrations occur within 6-8 hours following a single oral administration of a 40 mg dose. The oral solution and delayed-release capsule are bioequivalent. Food does not affect the systemic bioavailability of fluoxetine but it delays the absorption by 1-2 hours (not clinically significant). Prozac Weekly capsules, a delayed–release formulation, contain enteric–coated pellets that resist dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5. The enteric coating delays the onset of absorption of fluoxetine 1 to 2 hours relative to the immediate–release formulations.

Volume of distribution
  • 20-45 L/kg
Protein binding

94.5% bound to human serum proteins, including albumin and alpha-1-glycoprotein.

Metabolism

Limited data from animal studies suggest that fluoxetine may undergo first-pass metabolism may occur via the liver and/or lungs. Fluoxetine appears to be extensively metabolized, likely in the liver, to norfluoxetine and other metabolites. Norfluoxetine, the principal active metabolite, is formed via N-demethylation of fluoxetine. Norfluoxetine appears to be comparable pharmacologic potency as fluoxetine. Fluoxetine and norfluoxetine both undergo phase II glucuronidation reactions in the liver. It is also thought that fluoxetine and norfluoxetine undergo O-dealkylation to form p-trifluoromethylphenol, which is then subsequently metabolized to hippuric acid.

Route of elimination

The primary route of elimination appears to be hepatic metabolism to inactive metabolites excreted by the kidney. The S-enantiomer is eliminated more slowly and is the predominant enantiomer present at steady state.

Half life

1-3 days [acute administration]; 4-6 days [chronic administration]; 4-16 days [norfluoxetine, acute and chronic administration].

Clearance
Not Available
Toxicity

Symptoms of overdose include agitation, restlessness, hypomania, and other signs of CNS excitation. LD50=284mg/kg (orally in mice). The most frequent side effects include: nervous system effects such as anxiety, nervousness, insomnia, drowsiness, fatigue or asthenia, tremor, and dizziness or lightheadedness; GI effects such as anorexia, nausea, and diarrhea; vasodilation; dry mouth; abnormal vision; decreased libido; abnormal ejaculation; rash; and sweating. Withdrawal symptoms include flu-like symptoms, insomnia, nausea, imbalance, sensory changes and hyperactivity.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Fluoxetine Action PathwayDrug action
Fluoxetine Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Fluoxetine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluoxetine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Fluoxetine.Experimental
AbirateroneThe serum concentration of Fluoxetine can be increased when it is combined with Abiraterone.Approved
AcarboseFluoxetine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Fluoxetine.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Fluoxetine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluoxetine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Fluoxetine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Fluoxetine.Approved
Acetylsalicylic acidFluoxetine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Fluoxetine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Fluoxetine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Fluoxetine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fluoxetine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Fluoxetine.Approved, Investigational
AlaproclateFluoxetine may increase the serotonergic activities of Alaproclate.Experimental
AlbiglutideFluoxetine may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fluoxetine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Fluoxetine.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Fluoxetine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Fluoxetine.Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Fluoxetine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Fluoxetine.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Fluoxetine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Fluoxetine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluoxetine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Fluoxetine.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Fluoxetine.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Fluoxetine.Approved, Investigational
AmineptineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amineptine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Fluoxetine.Approved, Withdrawn
AmiodaroneThe metabolism of Fluoxetine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluoxetine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amoxapine.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Fluoxetine.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Fluoxetine.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Fluoxetine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Fluoxetine.Approved
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Fluoxetine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Fluoxetine.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Fluoxetine.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
AprepitantThe serum concentration of Fluoxetine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Fluoxetine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Fluoxetine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Fluoxetine.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Fluoxetine.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Fluoxetine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Fluoxetine.Approved, Withdrawn
AtazanavirThe metabolism of Fluoxetine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Fluoxetine.Approved
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Fluoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Atorvastatin.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Fluoxetine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Azaperone.Investigational, Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Fluoxetine.Approved
AzithromycinThe metabolism of Fluoxetine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fluoxetine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fluoxetine.Illicit
BedaquilineBedaquiline may increase the QTc-prolonging activities of Fluoxetine.Approved
BefunololThe serum concentration of Befunolol can be increased when it is combined with Fluoxetine.Experimental
BendroflumethiazideFluoxetine may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Fluoxetine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Fluoxetine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fluoxetine.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Fluoxetine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Fluoxetine.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Fluoxetine.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Fluoxetine.Approved
BezitramideBezitramide may increase the serotonergic activities of Fluoxetine.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Bifeprunox.Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Fluoxetine.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Fluoxetine.Investigational
BoceprevirThe metabolism of Fluoxetine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Fluoxetine.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
BosentanThe serum concentration of Fluoxetine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fluoxetine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluoxetine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Fluoxetine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Fluoxetine.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Fluoxetine.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Brofaromine.Experimental
BromazepamThe metabolism of Bromazepam can be decreased when combined with Fluoxetine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Fluoxetine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Fluoxetine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Fluoxetine.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Fluoxetine.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Fluoxetine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Fluoxetine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Fluoxetine.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Fluoxetine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Fluoxetine.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Fluoxetine.Approved
BuspironeBuspirone may increase the serotonergic activities of Fluoxetine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluoxetine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Fluoxetine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Fluoxetine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Fluoxetine.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fluoxetine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Fluoxetine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluoxetine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Fluoxetine.Approved
CanagliflozinFluoxetine may increase the hypoglycemic activities of Canagliflozin.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Fluoxetine.Investigational
CapecitabineThe metabolism of Fluoxetine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Fluoxetine.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Fluoxetine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Fluoxetine.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Fluoxetine.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Fluoxetine.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Fluoxetine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Fluoxetine.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Fluoxetine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Fluoxetine.Approved, Investigational
CelecoxibFluoxetine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Fluoxetine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Fluoxetine.Approved, Vet Approved
CeritinibThe serum concentration of Fluoxetine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Fluoxetine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fluoxetine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Fluoxetine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluoxetine.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Fluoxetine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Fluoxetine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fluoxetine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluoxetine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Fluoxetine.Approved, Vet Approved
ChlorothiazideFluoxetine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Fluoxetine.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Fluoxetine.Experimental
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Fluoxetine.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Fluoxetine.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneFluoxetine may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Fluoxetine.Approved
CholecalciferolThe metabolism of Fluoxetine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Fluoxetine.Approved
CimetidineThe metabolism of Fluoxetine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Fluoxetine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluoxetine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Fluoxetine.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Fluoxetine.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Fluoxetine.Approved
ClarithromycinThe metabolism of Fluoxetine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Fluoxetine can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Fluoxetine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Fluoxetine.Approved
ClobazamThe metabolism of Fluoxetine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Fluoxetine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Fluoxetine.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Fluoxetine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Clopenthixol.Experimental
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Fluoxetine resulting in a loss in efficacy.Approved, Nutraceutical
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Fluoxetine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluoxetine.Approved, Illicit
ClorindioneFluoxetine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Clothiapine.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Fluoxetine.Approved, Illicit
ClotrimazoleThe metabolism of Fluoxetine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Fluoxetine.Approved
CobicistatThe serum concentration of Fluoxetine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Fluoxetine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Fluoxetine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Fluoxetine.Approved
ConivaptanThe serum concentration of Fluoxetine can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Fluoxetine can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Fluoxetine can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Fluoxetine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Cyclobenzaprine.Approved
CyclopenthiazideFluoxetine may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Fluoxetine.Approved, Investigational
CyclosporineThe metabolism of Fluoxetine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Fluoxetine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluoxetine.Approved
DabrafenibThe serum concentration of Fluoxetine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fluoxetine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Fluoxetine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fluoxetine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Fluoxetine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Fluoxetine.Approved, Investigational
DarunavirThe serum concentration of Fluoxetine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Fluoxetine.Approved
DasatinibThe serum concentration of Fluoxetine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Fluoxetine.Approved, Investigational
DeferasiroxThe serum concentration of Fluoxetine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Fluoxetine.Approved
DelavirdineThe metabolism of Fluoxetine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Fluoxetine.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Fluoxetine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fluoxetine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Fluoxetine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Fluoxetine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluoxetine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Fluoxetine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Fluoxetine.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Fluoxetine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluoxetine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Fluoxetine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Fluoxetine.Approved, Illicit
DextromethorphanFluoxetine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Fluoxetine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Fluoxetine.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the serotonergic activities of Fluoxetine.Approved, Investigational
DiazepamThe metabolism of Diazepam can be decreased when combined with Fluoxetine.Approved, Illicit, Vet Approved
DibenzepinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Dibenzepin.Experimental
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Fluoxetine.Approved, Vet Approved
DicoumarolFluoxetine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Fluoxetine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Fluoxetine.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Fluoxetine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fluoxetine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fluoxetine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Fluoxetine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluoxetine.Approved
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Fluoxetine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Fluoxetine.Experimental, Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Fluoxetine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fluoxetine.Approved
DiphenadioneFluoxetine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Fluoxetine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Fluoxetine.Approved, Illicit
DisopyramideFluoxetine may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Dixyrazine.Experimental
DofetilideThe risk or severity of QTc prolongation can be increased when Dofetilide is combined with Fluoxetine.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Fluoxetine.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Fluoxetine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Fluoxetine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Fluoxetine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Fluoxetine.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Fluoxetine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fluoxetine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Fluoxetine.Approved, Investigational
DoxycyclineThe metabolism of Fluoxetine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Fluoxetine.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Fluoxetine.Investigational
DronabinolThe metabolism of Dronabinol can be decreased when combined with Fluoxetine.Approved, Illicit
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Fluoxetine.Approved
DroperidolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Droperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fluoxetine.Experimental, Illicit
DulaglutideFluoxetine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Fluoxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluoxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fluoxetine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Fluoxetine.Approved
EfavirenzThe metabolism of Fluoxetine can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Fluoxetine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Fluoxetine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Fluoxetine.Investigational
EmpagliflozinFluoxetine may increase the hypoglycemic activities of Empagliflozin.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Fluoxetine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Fluoxetine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Fluoxetine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fluoxetine.Approved, Investigational, Vet Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Fluoxetine.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Fluoxetine.Approved, Investigational
EnzalutamideThe serum concentration of Fluoxetine can be decreased when it is combined with Enzalutamide.Approved
EpanololThe serum concentration of Epanolol can be increased when it is combined with Fluoxetine.Experimental
EpinastineThe metabolism of Epinastine can be decreased when combined with Fluoxetine.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Fluoxetine.Approved, Investigational
ErythromycinThe metabolism of Fluoxetine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Fluoxetine.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Fluoxetine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Esmirtazapine.Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Fluoxetine.Approved
EsomeprazoleThe metabolism of Fluoxetine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluoxetine.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Fluoxetine.Approved, Investigational, Vet Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluoxetine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fluoxetine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluoxetine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluoxetine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fluoxetine.Approved
Ethyl biscoumacetateFluoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluoxetine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Fluoxetine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluoxetine.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Fluoxetine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Fluoxetine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Fluoxetine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Fluoxetine.Approved
EtodolacFluoxetine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluoxetine.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Fluoxetine.Withdrawn
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Fluoxetine.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Fluoxetine.Illicit, Vet Approved
EtravirineThe metabolism of Etravirine can be decreased when combined with Fluoxetine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Fluoxetine.Approved
ExenatideFluoxetine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Fluoxetine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Fluoxetine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Fluoxetine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineFluoxetine may increase the serotonergic activities of Fenfluramine.Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluoxetine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Fluoxetine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Fluoxetine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fluoxetine.Approved
FloxuridineThe metabolism of Fluoxetine can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fluanisone.Experimental
FluconazoleFluconazole may increase the QTc-prolonging activities of Fluoxetine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluoxetine.Approved, Illicit
FluindioneFluoxetine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Fluoxetine.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Fluoxetine.Approved, Illicit
FluorouracilThe metabolism of Fluoxetine can be decreased when combined with Fluorouracil.Approved
FlupentixolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Fluoxetine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluoxetine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fluspirilene.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Fluoxetine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fluoxetine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Fluoxetine.Approved
FluvoxamineThe metabolism of Fluoxetine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
FosamprenavirThe metabolism of Fluoxetine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fluoxetine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Fluoxetine.Approved
FosphenytoinFosphenytoin may increase the QTc-prolonging activities of Fluoxetine.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fluoxetine.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Fluoxetine.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Fluoxetine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluoxetine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Fluoxetine.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Fluoxetine.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Fluoxetine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fluoxetine.Approved, Illicit, Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Fluoxetine.Approved, Investigational
GemfibrozilThe metabolism of Fluoxetine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Fluoxetine.Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Fluoxetine.Approved
GlimepirideFluoxetine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideFluoxetine may increase the hypoglycemic activities of Glipizide.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Fluoxetine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fluoxetine.Approved, Illicit
GlyburideThe metabolism of Glyburide can be decreased when combined with Fluoxetine.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Fluoxetine.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Fluoxetine.Approved, Investigational
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Fluoxetine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fluoxetine.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Fluoxetine.Approved
HaloperidolFluoxetine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Fluoxetine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Fluoxetine.Approved, Illicit, Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Fluoxetine.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Fluoxetine.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Fluoxetine.Experimental
HydrochlorothiazideFluoxetine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Fluoxetine resulting in a loss in efficacy.Approved, Illicit
HydroflumethiazideFluoxetine may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Fluoxetine.Approved, Illicit
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Fluoxetine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Fluoxetine.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Fluoxetine.Approved
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Fluoxetine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Fluoxetine.Approved
IdelalisibThe serum concentration of Fluoxetine can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Fluoxetine.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Fluoxetine.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Fluoxetine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Fluoxetine.Approved
IndalpineIndalpine may increase the serotonergic activities of Fluoxetine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Fluoxetine.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Fluoxetine.Withdrawn
IndinavirThe metabolism of Fluoxetine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Fluoxetine.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Fluoxetine.Approved, Investigational
Insulin AspartFluoxetine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirFluoxetine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineFluoxetine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineFluoxetine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanFluoxetine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproFluoxetine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Fluoxetine.Approved, Investigational
Ioflupane I-123Fluoxetine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Fluoxetine.Approved
IprindoleThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Iprindole.Experimental
IproclozideIproclozide may increase the serotonergic activities of Fluoxetine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Fluoxetine.Withdrawn
IrbesartanThe metabolism of Fluoxetine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Fluoxetine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Isocarboxazid.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
IsoniazidThe metabolism of Fluoxetine can be decreased when combined with Isoniazid.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Fluoxetine.Approved
ItraconazoleThe metabolism of Fluoxetine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Fluoxetine.Approved
IvacaftorThe serum concentration of Fluoxetine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Fluoxetine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluoxetine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluoxetine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Fluoxetine.Approved, Investigational
KetoconazoleThe metabolism of Fluoxetine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Fluoxetine.Approved, Nutraceutical, Withdrawn
LabetalolThe metabolism of Labetalol can be decreased when combined with Fluoxetine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluoxetine.Approved, Investigational
LandiololThe serum concentration of Landiolol can be increased when it is combined with Fluoxetine.Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Fluoxetine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Fluoxetine.Approved
LeflunomideThe metabolism of Fluoxetine can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Fluoxetine.Approved
LetermovirThe metabolism of Letermovir can be decreased when combined with Fluoxetine.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluoxetine.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Fluoxetine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fluoxetine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Fluoxetine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Fluoxetine.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Fluoxetine.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Fluoxetine.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Fluoxetine.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Fluoxetine.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluoxetine.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Fluoxetine.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Fluoxetine.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluoxetine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Fluoxetine.Approved
LiraglutideFluoxetine may increase the hypoglycemic activities of Liraglutide.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Fluoxetine.Approved, Investigational
LithiumLithium may increase the serotonergic activities of Fluoxetine.Approved
LobeglitazoneThe metabolism of Fluoxetine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilLofentanil may increase the serotonergic activities of Fluoxetine.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Lofepramine.Experimental
LomustineThe metabolism of Lomustine can be decreased when combined with Fluoxetine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Fluoxetine.Approved
LopinavirThe metabolism of Fluoxetine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Fluoxetine.Experimental
LoratadineThe metabolism of Loratadine can be decreased when combined with Fluoxetine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluoxetine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Fluoxetine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Fluoxetine.Approved
LosartanThe metabolism of Fluoxetine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Fluoxetine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Fluoxetine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Fluoxetine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Fluoxetine can be decreased when combined with Lumefantrine.Approved
LumiracoxibFluoxetine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Lurasidone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Fluoxetine.Illicit, Investigational, Withdrawn
MacitentanThe metabolism of Macitentan can be decreased when combined with Fluoxetine.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Fluoxetine.Approved, Vet Approved
ManidipineThe metabolism of Fluoxetine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Fluoxetine.Approved
MebanazineMebanazine may increase the serotonergic activities of Fluoxetine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Fluoxetine.Experimental
MecaserminFluoxetine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Fluoxetine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Fluoxetine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Fluoxetine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Fluoxetine.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Fluoxetine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Melperone.Approved, Investigational
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Fluoxetine.Investigational, Withdrawn
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Fluoxetine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluoxetine.Approved, Vet Approved
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Fluoxetine.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Fluoxetine.Experimental
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Fluoxetine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Fluoxetine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluoxetine.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Fluoxetine.Experimental
MetforminFluoxetine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Fluoxetine.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Fluoxetine.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Fluoxetine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluoxetine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluoxetine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluoxetine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluoxetine.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Fluoxetine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Fluoxetine.Approved, Investigational, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Fluoxetine.Approved
MethyclothiazideFluoxetine may increase the hyponatremic activities of Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Fluoxetine.Experimental
Methylene blueFluoxetine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Fluoxetine.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Fluoxetine.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Fluoxetine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Fluoxetine.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Fluoxetine.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Fluoxetine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluoxetine.Approved, Investigational
MetolazoneFluoxetine may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fluoxetine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Fluoxetine.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Fluoxetine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Fluoxetine.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Fluoxetine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Fluoxetine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluoxetine.Approved, Illicit
MidostaurinThe metabolism of Fluoxetine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Fluoxetine can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolFluoxetine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Fluoxetine.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Fluoxetine.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Mirtazapine.Approved
MitotaneThe serum concentration of Fluoxetine can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Fluoxetine.Approved
ModafinilThe metabolism of Fluoxetine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Fluoxetine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Fluoxetine.Approved, Investigational, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Fluoxetine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Mosapramine.Experimental
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Fluoxetine.Approved, Investigational
NabumetoneFluoxetine may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Fluoxetine.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Fluoxetine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Fluoxetine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Naratriptan.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Fluoxetine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Fluoxetine.Approved, Investigational
NefazodoneThe metabolism of Fluoxetine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Fluoxetine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Fluoxetine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Fluoxetine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Fluoxetine.Withdrawn
NicardipineNicardipine may increase the QTc-prolonging activities of Fluoxetine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Fluoxetine.Approved, Investigational
NicomorphineNicomorphine may increase the serotonergic activities of Fluoxetine.Experimental
NicotineThe metabolism of Nicotine can be decreased when combined with Fluoxetine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Nifedipine.Approved
NilotinibThe metabolism of Fluoxetine can be decreased when combined with Nilotinib.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Fluoxetine.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Fluoxetine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Fluoxetine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluoxetine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Fluoxetine.Approved, Investigational, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fluoxetine.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Fluoxetine.Investigational
NormethadoneNormethadone may increase the serotonergic activities of Fluoxetine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Nortriptyline.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Fluoxetine.Withdrawn
OctreotideOctreotide may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
OlaparibThe metabolism of Fluoxetine can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Fluoxetine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluoxetine.Approved
OmeprazoleThe metabolism of Fluoxetine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Fluoxetine.Approved
OpipramolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Opipramol.Investigational
OpiumOpium may increase the serotonergic activities of Fluoxetine.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fluoxetine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Fluoxetine can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Fluoxetine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluoxetine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Fluoxetine.Approved, Investigational
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Fluoxetine.Approved
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Fluoxetine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluoxetine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Fluoxetine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Fluoxetine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Oxypertine.Experimental
OxytocinOxytocin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
PalbociclibThe serum concentration of Fluoxetine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Fluoxetine.Approved, Investigational
PanobinostatThe serum concentration of Fluoxetine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Fluoxetine can be decreased when combined with Pantoprazole.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Fluoxetine.Approved, Investigational
ParecoxibFluoxetine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Fluoxetine.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Fluoxetine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fluoxetine.Approved
Peginterferon alfa-2bThe serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Fluoxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Penfluridol.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Fluoxetine.Approved
PentazocinePentazocine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
PentobarbitalThe metabolism of Fluoxetine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Fluoxetine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Fluoxetine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Fluoxetine.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Fluoxetine.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Fluoxetine.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Fluoxetine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Fluoxetine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Fluoxetine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Fluoxetine.Withdrawn
PhenazocinePhenazocine may increase the serotonergic activities of Fluoxetine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Phenelzine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Fluoxetine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Fluoxetine.Experimental
PhenindioneFluoxetine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Fluoxetine.Withdrawn
PhenobarbitalThe metabolism of Fluoxetine can be increased when combined with Phenobarbital.Approved
PhenoperidinePhenoperidine may increase the serotonergic activities of Fluoxetine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Fluoxetine.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Fluoxetine.Withdrawn
PhenprocoumonFluoxetine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
PimozideFluoxetine may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Fluoxetine.Approved
PioglitazoneFluoxetine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Pipamperone.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Fluoxetine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Fluoxetine.Approved, Investigational
PiritramidePiritramide may increase the serotonergic activities of Fluoxetine.Investigational
PirlindolePirlindole may increase the serotonergic activities of Fluoxetine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Fluoxetine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Fluoxetine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Fluoxetine.Approved
Platelet Activating FactorThe serum concentration of Platelet Activating Factor can be increased when it is combined with Fluoxetine.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Fluoxetine.Approved
PolythiazideFluoxetine may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluoxetine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Fluoxetine.Approved
PosaconazoleThe metabolism of Fluoxetine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Fluoxetine.Approved
PramlintideFluoxetine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fluoxetine.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Fluoxetine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Fluoxetine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluoxetine.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Fluoxetine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluoxetine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fluoxetine.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Fluoxetine.Approved
PrimidoneThe metabolism of Fluoxetine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Fluoxetine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fluoxetine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Procarbazine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Fluoxetine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Fluoxetine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Fluoxetine.Approved
PromazineThe metabolism of Fluoxetine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Fluoxetine.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Fluoxetine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Fluoxetine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluoxetine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Propericiazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Fluoxetine.Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Fluoxetine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Fluoxetine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Fluoxetine.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Fluoxetine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Fluoxetine.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Fluoxetine.Approved
PyrimethamineThe metabolism of Fluoxetine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Fluoxetine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Fluoxetine.Approved
QuinethazoneFluoxetine may increase the hyponatremic activities of Quinethazone.Approved
QuinidineThe metabolism of Fluoxetine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Fluoxetine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Fluoxetine.Experimental
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Fluoxetine.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Raclopride.Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Fluoxetine.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Fluoxetine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Fluoxetine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Rasagiline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Fluoxetine.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Fluoxetine.Approved, Withdrawn
RepaglinideFluoxetine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Fluoxetine.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Reserpine.Approved, Investigational
RifabutinThe metabolism of Fluoxetine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Fluoxetine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fluoxetine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Fluoxetine.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Fluoxetine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Fluoxetine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ritanserin.Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Rizatriptan.Approved
RofecoxibFluoxetine may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RolapitantThe metabolism of Fluoxetine can be decreased when combined with Rolapitant.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Fluoxetine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Fluoxetine.Vet Approved
RopiniroleThe metabolism of Fluoxetine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Fluoxetine.Approved
RosiglitazoneFluoxetine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Fluoxetine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Fluoxetine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Fluoxetine.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Fluoxetine.Approved
SafrazineSafrazine may increase the serotonergic activities of Fluoxetine.Withdrawn
SalbutamolSalbutamol may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Fluoxetine.Approved
SaquinavirThe metabolism of Fluoxetine can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinFluoxetine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluoxetine.Approved
SecobarbitalThe metabolism of Fluoxetine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Fluoxetine.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Fluoxetine.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Fluoxetine.Approved, Investigational, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Fluoxetine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Fluoxetine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fluoxetine.Approved
SiltuximabThe serum concentration of Fluoxetine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fluoxetine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Fluoxetine.Approved
SitagliptinFluoxetine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Fluoxetine.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Fluoxetine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
SotalolThe serum concentration of Sotalol can be increased when it is combined with Fluoxetine.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Fluoxetine.Experimental
St. John's WortThe serum concentration of Fluoxetine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Fluoxetine can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the serotonergic activities of Fluoxetine.Approved, Investigational
SulfadiazineThe metabolism of Fluoxetine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Fluoxetine.Approved
SulfisoxazoleThe metabolism of Fluoxetine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Fluoxetine.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Fluoxetine.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Fluoxetine.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Fluoxetine resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Fluoxetine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Fluoxetine.Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Fluoxetine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Fluoxetine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Fluoxetine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Fluoxetine.Investigational, Withdrawn
TelaprevirThe metabolism of Fluoxetine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Fluoxetine.Approved
TelithromycinThe metabolism of Fluoxetine can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Fluoxetine.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Fluoxetine.Approved
Tenofovir disoproxilThe metabolism of Fluoxetine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Fluoxetine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Fluoxetine.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Fluoxetine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Fluoxetine.Experimental
TeriflunomideThe serum concentration of Fluoxetine can be decreased when it is combined with Teriflunomide.Approved
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Fluoxetine.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Fluoxetine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Fluoxetine.Approved, Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Fluoxetine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fluoxetine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fluoxetine.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Fluoxetine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Fluoxetine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluoxetine.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Fluoxetine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Fluoxetine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluoxetine.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Thioproperazine.Approved
ThioridazineFluoxetine may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
ThiotepaThe metabolism of Fluoxetine can be decreased when combined with Thiotepa.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Fluoxetine.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Fluoxetine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fluoxetine.Approved
TianeptineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Fluoxetine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Fluoxetine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Fluoxetine.Vet Approved
TilidineTilidine may increase the serotonergic activities of Fluoxetine.Experimental
TimololThe metabolism of Timolol can be decreased when combined with Fluoxetine.Approved
TioclomarolFluoxetine may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Fluoxetine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Fluoxetine.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Fluoxetine.Approved
TocilizumabThe serum concentration of Fluoxetine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Fluoxetine.Approved, Investigational
TolazamideFluoxetine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideThe metabolism of Fluoxetine can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluoxetine.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Fluoxetine.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
TopiramateThe metabolism of Fluoxetine can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Fluoxetine can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Fluoxetine.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Fluoxetine.Approved, Investigational
TramadolFluoxetine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fluoxetine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluoxetine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Fluoxetine.Vet Approved
TrichlormethiazideFluoxetine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Fluoxetine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluoxetine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluoxetine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Fluoxetine.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fluoxetine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Fluoxetine.Investigational, Withdrawn
TropisetronTropisetron may increase the serotonergic activities of Fluoxetine.Approved, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Fluoxetine.Approved, Experimental
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Fluoxetine.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Fluoxetine.Approved, Investigational
ValdecoxibFluoxetine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Fluoxetine.Approved, Investigational
ValsartanThe metabolism of Fluoxetine can be decreased when combined with Valsartan.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Fluoxetine.Approved
VemurafenibThe serum concentration of Fluoxetine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Fluoxetine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Veralipride.Experimental
VerapamilThe metabolism of Fluoxetine can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Fluoxetine.Approved, Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Fluoxetine.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Fluoxetine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Fluoxetine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Fluoxetine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Fluoxetine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Fluoxetine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Fluoxetine.Experimental
VoriconazoleThe metabolism of Fluoxetine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Fluoxetine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Fluoxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Fluoxetine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Fluoxetine.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Fluoxetine.Approved, Vet Approved
ZafirlukastThe metabolism of Fluoxetine can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Fluoxetine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluoxetine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fluoxetine.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Fluoxetine.Approved
ZimelidineFluoxetine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneFluoxetine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Fluoxetine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluoxetine.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Fluoxetine.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fluoxetine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fluoxetine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Zotepine.Approved, Investigational
ZucapsaicinThe metabolism of Fluoxetine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Fluoxetine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation and nausea.

References

Synthesis Reference

Eduard Schwartz, Joseph Kaspi, Zinovi Itov, Gidon Pilarski, "Production of fluoxetine and new intermediates." U.S. Patent US5225585, issued October, 1990.

US5225585
General References
  1. Wong DT, Bymaster FP, Engleman EA: Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 1995;57(5):411-41. [PubMed:7623609]
  2. Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB: A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci. 1974 Aug 1;15(3):471-9. [PubMed:4549929]
  3. Carlsson A, Wong DT: Correction: a note on the discovery of selective serotonin reuptake inhibitors. Life Sci. 1997;61(12):1203. [PubMed:9315511]
  4. Gerber PE, Lynd LD: Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998 Jun;32(6):692-8. [PubMed:9640489]
  5. Caley CF: Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother. 1997 Dec;31(12):1481-9. [PubMed:9416386]
External Links
Human Metabolome Database
HMDB14615
KEGG Drug
D00823
PubChem Compound
3386
PubChem Substance
46507902
ChemSpider
3269
BindingDB
30130
ChEBI
86990
ChEMBL
CHEMBL41
Therapeutic Targets Database
DAP000186
PharmGKB
PA449673
IUPHAR
203
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fluoxetine
ATC Codes
N06CA03 — Fluoxetine and psycholepticsN06AB03 — Fluoxetine
AHFS Codes
  • 28:16.04.20 — Selective-serotonin Reuptake Inhibitors
FDA label
Download (194 KB)
MSDS
Download (76.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingOtherDiabetes, Diabetes Mellitus Type 11
0Not Yet RecruitingPreventionCognitive Dysfunctions1
0RecruitingTreatmentDiabetes, Diabetes Mellitus Type 1 / Hypoglycemia Associated Autonomic Failure1
1CompletedNot AvailableHealthy Volunteers4
1CompletedTreatmentCancer, Advanced / Obese experiencing rapid weight loss1
1CompletedTreatmentDepression2
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentMajor Depressive Disorder (MDD)2
1, 2CompletedHealth Services ResearchAdolescent Depression2
1, 2CompletedTreatmentHypochondriasis1
1, 2RecruitingTreatmentSyndrome X1
2Active Not RecruitingTreatmentSecondary Progressive Multiple Sclerosis (SPMS)1
2CompletedSupportive CareMultiple System Atrophy (MSA)1
2CompletedTreatmentAlcoholism / Depression1
2CompletedTreatmentAnxiety Disorders / Depression / Lung Cancers / Tiredness1
2CompletedTreatmentAutistic Disorder1
2CompletedTreatmentBack Pain / Sciatica1
2CompletedTreatmentCannabis Abuse / Major Depressive Disorder (MDD)1
2CompletedTreatmentCocaine-Related Disorders1
2CompletedTreatmentDepression1
2CompletedTreatmentDepression / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentDomestic Violence1
2CompletedTreatmentFibromyalgia / Growth Hormone Deficiency (GHD)1
2CompletedTreatmentIntermittent Explosive Disorder1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentMajor Depressive Disorder (MDD) / Unipolar Depression1
2CompletedTreatmentMenopausal and Postmenopausal Disorders / Moderate Depression1
2CompletedTreatmentMotor Impairments / Stroke, Ischemic1
2CompletedTreatmentPulmonary Arterial Hypertension (PAH)1
2CompletedTreatmentSevere Mood Dysregulation1
2RecruitingPreventionEpilepsies / Sudden unexplained death in epilepsy1
2RecruitingTreatmentMotor Function / Strokes1
2RecruitingTreatmentStroke, Acute / Visual Field Loss1
2TerminatedTreatmentMajor Depressive Disorder (MDD)1
2TerminatedTreatmentObsessive-Compulsive Disorder (OCD)1
2WithdrawnTreatmentAutism, Early Infantile1
2WithdrawnTreatmentSevere Stroke With Affected Arm Motor Function1
2, 3CompletedTreatmentDepression1
2, 3CompletedTreatmentDepression / Suicide, Attempted1
2, 3CompletedTreatmentNon-erosive Reflux Disease (NERD)1
3CompletedTreatmentAnxiety Disorders1
3CompletedTreatmentAutistic Disorder1
3CompletedTreatmentDepression1
3CompletedTreatmentDepression / Major Depressive Disorder (MDD)1
3CompletedTreatmentDepression / Major Depressive Disorder (MDD) / Nicotine Dependence1
3CompletedTreatmentDepression / Smoking1
3CompletedTreatmentEpilepsies / Ictal/Post-ictal Hypoxemia1
3CompletedTreatmentFibromyalgia / Juvenile Primary Fibromyalgia Syndrome (JPFS)1
3CompletedTreatmentMajor Depressive Disorder (MDD)8
3CompletedTreatmentSocial Phobia1
3CompletedTreatmentStress Disorders, Post-Traumatic1
3CompletedTreatmentTreatment Resistant Depression (TRD)1
3RecruitingTreatmentMajor Depressive Disorder (MDD)4
3RecruitingTreatmentPersonality Disorders / Psychotic Disorder NOS1
3RecruitingTreatmentPremenstrual Syndrome3
3RecruitingTreatmentStrokes1
3TerminatedSupportive CareIntracerebral Hemorrhage / Motor Impairments1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentAutistic Disorder1
3TerminatedTreatmentBipolar Disorder (BD) / Depression1
3TerminatedTreatmentTreatment Resistant Depression (TRD)1
4CompletedBasic ScienceMajor Depressive Disorder (MDD)1
4CompletedDiagnosticMajor Depressive Disorder (MDD)1
4CompletedHealth Services ResearchHealthy Volunteers1
4CompletedHealth Services ResearchObsessive Compulsive Disorder (OCD)1
4CompletedOtherHealthy Controls / Major Depressive Disorder (MDD)1
4CompletedTreatmentAlcohol Dependence / Alcoholism / Depression1
4CompletedTreatmentAlcohol-Related Disorders / Marijuana Abuse / Substance-Related Disorders1
4CompletedTreatmentAnorexia Nervosa (AN) / Eating Disorders1
4CompletedTreatmentAnxiety Disorders / Moods Disorders / Schizophrenic Disorders1
4CompletedTreatmentBipolar Disorder (BD)3
4CompletedTreatmentBipolar Disorder (BD) / Depression1
4CompletedTreatmentBody Dysmorphic Disorders1
4CompletedTreatmentBorderline Personality Disorder (BPD)1
4CompletedTreatmentDepression1
4CompletedTreatmentDepression, Bipolar2
4CompletedTreatmentDepression / Menopause1
4CompletedTreatmentDepressive Disorder NOS / Dysthymic Disorder / Major Depressive Disorder (MDD)1
4CompletedTreatmentMajor Depressive Disorder (MDD)6
4CompletedTreatmentObsessive Compulsive Disorder (OCD)1
4CompletedTreatmentObsessive-Compulsive Disorder (OCD)1
4CompletedTreatmentPremenstrual Dysphoric Disorder / Premenstrual Syndrome1
4CompletedTreatmentPsychotic Disorder NOS1
4RecruitingNot AvailableDepressive Disorders / Lactation1
4RecruitingBasic ScienceBipolar Disorder (BD)1
4RecruitingDiagnosticFragile X Syndrome (FXS) / Velocardiofacial Syndrome / Williams Syndrome1
4RecruitingOtherAttenuated Psychosis Syndrome1
4RecruitingTreatmentAnxiety Disorders / Obsessive-Compulsive Disorder (OCD) / Psychiatric Disorder NOS1
4RecruitingTreatmentBipolar Disorder (BD)1
4RecruitingTreatmentBulimia Nervosa (BN)1
4RecruitingTreatmentDepressive Disorders1
4RecruitingTreatmentEnd Stage Renal Disease (ESRD) / Major Depressive Disorder (MDD)1
4RecruitingTreatmentStrokes1
4TerminatedPreventionDepression1
4TerminatedTreatmentDepression1
4TerminatedTreatmentDepression / Relapsing Remitting Multiple Sclerosis (RRMS)1
4TerminatedTreatmentPediatric Bipolar Disorder / Pediatric OCD1
4Unknown StatusTreatmentAlcoholism / Depression / Suicidal Behaviour1
4Unknown StatusTreatmentAntidepressive Agents / Fluoxetine / Major Depressive Disorder (MDD) / Pharmacogenetics / Venlafaxine1
4Unknown StatusTreatmentBorderline Personality Disorder (BPD) / Suicide1
4Unknown StatusTreatmentDepression / Sleep Initiation and Maintenance Disorders1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)3
4Unknown StatusTreatmentPosttraumatic Stress Disorder, Combat-related1
4WithdrawnTreatmentDepression1
Not AvailableActive Not RecruitingNot AvailableAnxiety Disorders / Generalized Anxiety Disorder (GAD) / Obsessive-Compulsive Disorder (OCD) / Panic Disorders / Post-Traumatic Stress Disorder (PTSD) / Social Anxiety Disorder (SAD)1
Not AvailableActive Not RecruitingNot AvailableMajor Depressive Disorder (MDD)1
Not AvailableActive Not RecruitingDiagnosticGeneralized Anxiety Disorder (GAD) / Separation Anxiety Disorder / Social Phobia1
Not AvailableActive Not RecruitingTreatmentDepression1
Not AvailableCompletedNot AvailableAcute Kidney Injury (AKI) / Depression1
Not AvailableCompletedNot AvailableDiabetes, Diabetes Mellitus Type 11
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedBasic ScienceAnorexia Nervosa (AN)1
Not AvailableCompletedBasic ScienceDrug-Drug Interaction (DDI) / Healthy Volunteers1
Not AvailableCompletedBasic ScienceMajor Depressive Disorder (MDD)2
Not AvailableCompletedPreventionBipolar Disorder (BD) / Depression / Psychotic Disorder NOS / Schizophrenic Disorders1
Not AvailableCompletedPreventionCardiovascular Disease (CVD) / Heart Diseases1
Not AvailableCompletedPreventionDepression1
Not AvailableCompletedSupportive CareIctal Hypoventilation / Uncontrolled Partial Epilepsy1
Not AvailableCompletedTreatmentAutism, Early Infantile1
Not AvailableCompletedTreatmentAutistic Disorder1
Not AvailableCompletedTreatmentBulimia Nervosa (BN)1
Not AvailableCompletedTreatmentCancer, Advanced1
Not AvailableCompletedTreatmentCocaine-Related Disorders / Opioid-Related Disorders1
Not AvailableCompletedTreatmentDepersonalization Disorder1
Not AvailableCompletedTreatmentDepression4
Not AvailableCompletedTreatmentDepression / Major Depressive Disorder (MDD)1
Not AvailableCompletedTreatmentDepression / Strokes1
Not AvailableCompletedTreatmentEating Disorders1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)3
Not AvailableCompletedTreatmentObsessive-Compulsive Disorder (OCD)1
Not AvailableCompletedTreatmentPremenstrual Syndrome1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableEnrolling by InvitationTreatmentMenopausal Hot Flushes / Quality of Life1
Not AvailableNot Yet RecruitingTreatmentObsessive Compulsive Disorder (OCD)1
Not AvailableRecruitingNot AvailableObsessive-Compulsive Disorder (OCD)1
Not AvailableRecruitingTreatmentAlcohol-Related Disorders / Brain Injury / Chronic Diseases / Depression / Mild Cognitive Impairment (MCI) / Pain / Posttraumatic Stress Disorders / Quality of Life / Substance-Related Disorders / Suicidal Ideation / Wounds and Injuries1
Not AvailableRecruitingTreatmentGeneralized Anxiety Disorder (GAD)1
Not AvailableRecruitingTreatmentPost-stroke Depression1
Not AvailableTerminatedTreatmentAdolescent Depression1
Not AvailableTerminatedTreatmentCerebral Infarctions1
Not AvailableTerminatedTreatmentMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusTreatmentDepression1
Not AvailableUnknown StatusTreatmentMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1
Not AvailableWithdrawnNot AvailableDepression1
Not AvailableWithdrawnTreatmentPsychotic Disorder NOS1
Not AvailableWithdrawnTreatmentStrokes1

Pharmacoeconomics

Manufacturers
  • Barr laboratories inc
  • Dr reddys laboratories ltd
  • Eli lilly and co
  • Mutual pharmacal co
  • Watson laboratories inc
  • Alembic ltd
  • Alphapharm party ltd
  • Aurobindo pharma ltd
  • Beijing double crane pharmaceutical co ltd
  • Carlsbad technology inc
  • Dr reddys laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Landela pharmaceutical
  • Mallinckrodt inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Pliva inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Wockhardt ltd
  • Lilly research laboratories div eli lilly and co
  • Actavis mid atlantic llc
  • Aurobindo pharma usa inc
  • Hi tech pharmacal co inc
  • Lannett holdings inc
  • Novex pharma
  • Pharmaceutical assoc inc div beach products
  • Silarx pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Warner chilcott inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral20 mg/1
CapsuleOral40 mg/1
LiquidOral20 mg/5mL
SolutionOral20 mg/5mL
Tablet, film coatedOral60 mg/1
CapsuleOral10 mg/1
Capsule, delayed release pelletsOral90 mg/1
TabletOral10 mg/1
TabletOral20 mg/1
Tablet, coatedOral10 mg/1
Tablet, coatedOral20 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
CapsuleOral40 mg
Kit
SolutionOral20 mg
CapsuleOral
CapsuleOral60 mg
CapsuleOral20 mg
CapsuleOral10 mg
LiquidOral20 mg
Capsule, delayed releaseOral90 mg/1
Prices
Unit descriptionCostUnit
PROzac 20 mg/5ml Solution 120ml Bottle266.51USD bottle
PROzac Weekly 1 Package = 4 capsule (90 mg) Disp Pack140.77USD disp
Sarafem 7 10 mg tablet Box61.08USD box
Sarafem 7 20 mg tablet Each Box Contains 7 tablet59.55USD box
Prozac weekly 90 mg capsule34.5USD capsule
PROzac 40 mg capsule13.89USD capsule
Fluoxetine hcl powder8.32USD g
Sarafem 10 mg tablet7.91USD tablet
Sarafem 15 mg tablet7.91USD tablet
Sarafem 20 mg tablet7.91USD tablet
PROzac 20 mg capsule6.95USD capsule
PROzac 10 mg capsule6.77USD capsule
FLUoxetine HCl 40 mg capsule5.54USD capsule
PROzac 10 mg tablet4.31USD tablet
Fluoxetine hcl 20 mg tablet4.26USD tablet
Rapiflux 20 mg tablet3.11USD tablet
FLUoxetine HCl 20 mg capsule2.77USD capsule
Fluoxetine hcl 10 mg tablet2.72USD tablet
FLUoxetine HCl 10 mg capsule2.7USD capsule
Fxt 40 40 mg Capsule2.3USD capsule
Prozac 10 mg Capsule2.02USD capsule
Prozac 20 mg Capsule2.02USD capsule
Apo-Fluoxetine 10 mg Capsule1.13USD capsule
Co Fluoxetine 10 mg Capsule1.13USD capsule
Mylan-Fluoxetine 10 mg Capsule1.13USD capsule
Novo-Fluoxetine 10 mg Capsule1.13USD capsule
Nu-Fluoxetine 10 mg Capsule1.13USD capsule
Phl-Fluoxetine 10 mg Capsule1.13USD capsule
Pms-Fluoxetine 10 mg Capsule1.13USD capsule
Ratio-Fluoxetine Hydrochloride 10 mg Capsule1.13USD capsule
Sandoz Fluoxetine 10 mg Capsule1.13USD capsule
Apo-Fluoxetine 20 mg Capsule1.06USD capsule
Co Fluoxetine 20 mg Capsule1.06USD capsule
Mylan-Fluoxetine 20 mg Capsule1.06USD capsule
Novo-Fluoxetine 20 mg Capsule1.06USD capsule
Nu-Fluoxetine 20 mg Capsule1.06USD capsule
Phl-Fluoxetine 20 mg Capsule1.06USD capsule
Pms-Fluoxetine 20 mg Capsule1.06USD capsule
Ratio-Fluoxetine Hydrochloride 20 mg Capsule1.06USD capsule
Sandoz Fluoxetine 20 mg Capsule1.06USD capsule
FLUoxetine HCl 20 mg/5ml Solution1.03USD ml
Apo-Fluoxetine 4 mg/ml Liquid0.61USD liquid
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6960577No1997-11-012017-11-01Us
US5910319Yes1997-11-292017-11-29Us
US5985322Yes1997-11-292017-11-29Us
USRE39030No1997-05-292017-05-29Us
US5945416No1997-03-242017-03-24Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)179-182 °CNot Available
water solubility50 mg/mL at 25 °CNot Available
logP4.05ADLARD,M ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0017 mg/mLALOGPS
logP4.09ALOGPS
logP4.17ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area21.26 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity80.37 m3·mol-1ChemAxon
Polarizability30.33 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.983
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5899
P-glycoprotein inhibitor IInhibitor0.8565
P-glycoprotein inhibitor IIInhibitor0.5459
Renal organic cation transporterInhibitor0.5633
CYP450 2C9 substrateNon-substrate0.7475
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5754
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7149
Ames testNon AMES toxic0.7105
CarcinogenicityNon-carcinogens0.8089
BiodegradationNot ready biodegradable0.9868
Rat acute toxicity2.6048 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6058
hERG inhibition (predictor II)Inhibitor0.8467
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0006-9200000000-dcf68dbfd090c7fdfe11
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0009000000-ed61090013f0dc5f5c5a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0190000000-e9bcd2accdf5b7e40a88
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0590000000-04b1d4265cb156217f40
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0790000000-5c42b9a9a2cd0c4114aa
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0gb9-0960000000-88822d2fb3e7c0cdc0b3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-6b560941c92823b7901c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0109000000-1531c1e1630dcb42b497
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-53199cfe3b343ae81afd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0109000000-0e790a7e6032e51bfeb3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kf-9800000000-64d39c4a4fcc7f8b6f47
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kf-9700000000-e516356ce3eca65bece8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-6b560941c92823b7901c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zgi-1390000000-84c6bc70aefcd3758f31
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f7o-6940000000-a424e26ecc7465229968
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4m-0390000000-9b7253cd5718aa434e46
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4m-0290000000-d88f8004205c7223aa9f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01t9-0592000000-92a48c620c961fdb430f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0409000000-03f5678c6178e634f254
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-4900000000-2940e7bc3f6a559e61fc
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-5900000000-c904d50adb4d1ea90abd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-5900000000-5cbc74ddfe414085c9bd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-6b560941c92823b7901c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-f5f65bd85fe3483260bb

Taxonomy

Description
This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Trifluoromethylbenzenes
Direct Parent
Trifluoromethylbenzenes
Alternative Parents
Phenoxy compounds / Phenol ethers / Aralkylamines / Alkyl aryl ethers / Dialkylamines / Organopnictogen compounds / Organofluorides / Hydrocarbon derivatives / Alkyl fluorides
Substituents
Trifluoromethylbenzene / Phenoxy compound / Phenol ether / Alkyl aryl ether / Aralkylamine / Secondary aliphatic amine / Ether / Secondary amine / Organic oxygen compound / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether, secondary amino compound, (trifluoromethyl)benzenes (CHEBI:86990)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Richman A, Heinrichs SC: Seizure prophylaxis in an animal model of epilepsy by dietary fluoxetine supplementation. Epilepsy Res. 2007 Apr;74(1):19-27. Epub 2007 Jan 9. [PubMed:17215106]
  2. Iceta R, Mesonero JE, Alcalde AI: Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells. Life Sci. 2007 Mar 27;80(16):1517-24. Epub 2007 Jan 20. [PubMed:17289086]
  3. Mirza NR, Nielsen EO, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66. Epub 2007 Jan 30. [PubMed:17335951]
  4. Sanders AC, Hussain AJ, Hen R, Zhuang X: Chronic blockade or constitutive deletion of the serotonin transporter reduces operant responding for food reward. Neuropsychopharmacology. 2007 Nov;32(11):2321-9. Epub 2007 Mar 14. [PubMed:17356573]
  5. Goren MZ, Kucukibrahimoglu E, Berkman K, Terzioglu B: Fluoxetine partly exerts its actions through GABA: a neurochemical evidence. Neurochem Res. 2007 Sep;32(9):1559-65. Epub 2007 May 8. [PubMed:17486443]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Chiu PJ, Marcoe KF, Bounds SE, Lin CH, Feng JJ, Lin A, Cheng FC, Crumb WJ, Mitchell R: Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J Pharmacol Sci. 2004 Jul;95(3):311-9. [PubMed:15272206]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Chanrion B, Mannoury la Cour C, Gavarini S, Seimandi M, Vincent L, Pujol JF, Bockaert J, Marin P, Millan MJ: Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol Pharmacol. 2008 Mar;73(3):748-57. Epub 2007 Dec 14. [PubMed:18083778]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Cyclin-dependent protein serine/threonine kinase regulator activity
Specific Function
Binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function.
Gene Name
CKS1B
Uniprot ID
P61024
Uniprot Name
Cyclin-dependent kinases regulatory subunit 1
Molecular Weight
9660.14 Da
References
  1. Krishnan A, Hariharan R, Nair SA, Pillai MR: Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17. [PubMed:18371935]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577]
  2. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  3. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628]
  4. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624]
  5. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  6. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Not Available
Gene Name
CYP2B
Uniprot ID
Q14097
Uniprot Name
CYP2B protein
Molecular Weight
43147.81 Da
References
  1. Haduch A, Wojcikowski J, Daniel WA: Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacol Rep. 2008 Nov-Dec;60(6):957-65. [PubMed:19211989]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628]
  2. DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L: Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004 Feb;24(1):4-10. [PubMed:14709940]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS: (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. [PubMed:10997938]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS: (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. [PubMed:10997938]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34